Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 1 of 43 Examining vaccine effectiveness (VE) of FlublokÂ® Quadrivalent 
(Influenza Vaccine) relative to standard dose inactivated 
influenza vaccine among Kaiser Permanente Northern 
[LOCATION_004] members aged [ADDRESS_904131] dose inactivated influenza vaccine in adults  
 
Study Protocol  
Study Code : VAP00003  
Development Phase:  Phase IV  
Sponsor:  Kaiser Permanente Northern [LOCATION_004]  
Kaiser Permanente Vaccine Study Center  
[ADDRESS_904132](s):  Flublok Quadrivalent vaccine  
Standard-Dose Inactivated Influenza Vaccine (SD -IIV)*  
* to be determined prior to i nfluenza season  
Form  / Route:  Liquid/Intramuscular injection (0.5 mL)  
Indication For This Study : Comparative vaccine effectiveness of 2018 -2019 and 2019 -2020 
formulations  of Flublok Quadrivalent vaccine and SD -IIV in adults 18 
through 64 years of age  
Manufacturer:  [COMPANY_011] Pasteur Inc.  
Discovery Drive, Swiftwater, PA [ZIP_CODE]- 0187, [LOCATION_003]  
Principal Investigator : [INVESTIGATOR_174838], MD, PhD  
 
Contributing Investigators : Bruce Fireman, MA  
Ned Lewis, MPH 
Laurie Aukes, RN  
John Hansen, MPH  
Amber Hyman, MPH  
Project Manager and Study Leader  
 Amber Hyman, MPH  
  
Version and Date of the Protocol:  
Version 2.0 dated 8 May 2020  
 
ClinicalTrials.gov : [STUDY_ID_REMOVED]  
 
Information contained in this publication is the property of [COMPANY_011] Pasteur  and is confidential. This information may not be 
disclosed to third parties without written authorization from [COMPANY_011] Pasteur . This document may not be reproduced, stored in a 
retrieval system, or transmitted in any form or by [CONTACT_61076] â€“electronic, mechanical recording, or otherwise â€“without prior 
authorization from [COMPANY_011] Pasteur . This document must be returned to [COMPANY_011] Pasteur  upon request.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 2 of 43 History of Protocol Versions  
Table 1: Previous versions of the protocol  
Version*  Date  Comments  
0.[ADDRESS_904133] 2018  Final protocol sent to [COMPANY_011] from KPVSC  
* Versions in bold font have been approved by [CONTACT_11390](s) (IEC[s]) / Institutional Review 
Board(s) (IRB[s]) and used in the study.  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904134]  ................................................................................. 13 
1.3 Potential Benefits and Risks  ............................................................................... 13 
1.3.1  Potential Benefits to Subjects ........................................................................... 13 
1.3.2  Potential Risks to Subjects  ............................................................................... 13 
1.4 Rationale for the Study  ...................................................................................... 14 
2 Study Objectives  .................................................................................................  14 
2.1 Primary Objective  .............................................................................................. 14 
2.2 Secondary Objectives ......................................................................................... 14 
2.3 Exploratory Objectives  ...................................................................................... 15 
3 Investigators and Study Organization  ............................................................... 16 
4 Independent Ethics Committee / Institutional Review Bo ard .......................... 16 
5 Investigational Plan  ............................................................................................ 16 
5.1 Description of the Overall Study Design and Plan  .............................................. 16 
5.1.1  Study Design ................................................................................................... 16 
5.1.2  Justification of the Study Design ...................................................................... 16 
5.1.3  Study Plan  ....................................................................................................... 17 
5.1.4  Vaccine Distribution Procedures  ...................................................................... 18 
5.1.5  Planned Study Calendar  ................................................................................... 19 
5.2 Study Population ................................................................................................ 20 
5.2.1  Recruitment Procedures  ................................................................................... 20 
5.2.2  Informed Consent Procedures  .......................................................................... 20 
5.2.3  Screening Criteria  ............................................................................................ 20 
5.2.4  Inclusion Criteria  ............................................................................................. 20 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904135](s) ............................................................ [ADDRESS_904136](s)  ............................................................................. 22 
[IP_ADDRESS]  Composition .................................................................................................. 22 
[IP_ADDRESS]  Preparation and Administration  ..................................................................... 22 
[IP_ADDRESS]  Dose Selection and Timing  ............................................................................ [ADDRESS_904137](s)  ....................................................... 23 
[IP_ADDRESS]  Composition .................................................................................................. 23 
[IP_ADDRESS]  Preparation and Administration  ..................................................................... 23 
[IP_ADDRESS]  Dose Selection and Timing  ............................................................................ [ADDRESS_904138](s)  ............................................................................... [ADDRESS_904139] Shipment, Storage, and Accountability  ............................................... 24 
[IP_ADDRESS]  Product Shipment  .......................................................................................... 24 
[IP_ADDRESS]  Product Storage  ............................................................................................. 24 
[IP_ADDRESS]  Product Accountability  .................................................................................. 24 
6.3.3  Replacement Doses  ......................................................................................... 24 
6.3.4  Disposal of Unused Products  ........................................................................... 25 
6.3.5  Recall of Products ............................................................................................ 25 
6.4 Blinding and Code -breaking Procedures  ............................................................ 25 
6.5 Randomization and Allocation Procedures  ......................................................... 25 
6.6 Vaccine Administration Compliance  .................................................................. 26 
6.7 Concomitant Medications and Other Therapi[INVESTIGATOR_014]  .................................................. 26 
7 Management of Samples  .................................................................................... 26 
8 Endpoints and Assessment Methods  .................................................................  26 
8.1 Primary Endpoints and Assessment Methods  ..................................................... 26 
8.1.1  Relative Vaccine Effectiveness of Flublok Quadrivalent vaccine ..................... 26 
8.2 Secondary Endpoints and Assessment Methods  ................................................. 27 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904140] Has Completed the Study  ............ 30 
9.4 Assessment of Causality  .................................................................................... 30 
9.5 Reporting SAEs to Health Authorities and IECs / IRBs ...................................... 30 
10 Data Collection and Management  ..................................................................... 30 
10.1  Data Collection  .................................................................................................. 30 
10.2  Data Management  .............................................................................................. 31 
10.3  Data Review  ...................................................................................................... 31 
11 Statistical Methods and Determination of Sample Size .................................... 31 
11.1  Statistical Methods ............................................................................................. 31 
11.2  Sample Size and Power Calculations .................................................................. 32 
12 Ethical and Legal Issues and Investigator / Sponsor Responsibilities  .............. [ADDRESS_904141] of the Study / Good Clinical Practice ........................................ [ADDRESS_904142]  ..................................................................................................... 36 
14 Signature [CONTACT_3490] .................................................................................................... 37 
15 Appendi ces ......................................................................................................... 38 
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904143] of Tables  
Table 1: Previous versions of the protocol .....................................................................................2  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 7 of 43 Synopsis  
Company:  [COMPANY_011] Pasteur, Inc.  
Product s: Flublok Quadrivalent  (Influenza Vaccine)  
Active Substances:  â€¢ 45 Âµg hemagglutinin (HA) per virus strain per dose  
  Title of the Trial:  Examining vaccine effectiveness (VE) of FlublokÂ® Quadrivalent (Influenza 
Vaccine) relative to standard dose inactivated influenza vaccine  (SD-IIV)  
among Kaiser Permanente Northern [LOCATION_004] members aged 18-64 years  
Development Phase:  Phase IV  
Coordinating Investigator:  [INVESTIGATOR_174838], MD, PhD  
Study Sites:  Kaiser Permanente Northern [LOCATION_004]  
Planned Study  Period:  August 2018 to May 202 2 
Study  Design , Schedule of Study 
Procedures , and Methodology:  Multi -center, modified -cluster randomized study  
Early Safety Data Review:  N/A 
Interruption of the Study:  N/A 
Observational Objectives:  To estimate the relative vaccine effectiveness of Flublok Quadrivalent 
vaccine versus SD -IIV in adults [ADDRESS_904144] endpoints 
(specified below)  
Observational Endpoints:  PCR -confirmed influenza, hospi[INVESTIGATOR_669477], hospi[INVESTIGATOR_669478] -
acquired pneumonia, and cardio-respi[INVESTIGATOR_669479]:  ~2,400, 000 
Duration of Participation in the 
Study:  N/A; this is an observational, data -only study  
Licensed Study Product 1:  Flublok Quadrivalent vaccine  
 Form:  Single 0.5 mL dose  
 Composition:  â€¢ 45 mcg HA of each of influenza types and subtypes A (H1N1), A 
(H3N2), and two B lineages (B/Yamagata and B/Victoria)  
â€¢ sodium chloride (4.4 mg)  
â€¢ monobasic sodium phosphate (0.195 mcg)  
â€¢ dibasic sodium phosphate (1.3 mg), and polysorbate 20 (TweenÂ®20) 
(27.5 mcg)  
â€¢ may also contain residual amounts of baculovirus and Spodoptera 
frugiperda cell proteins (â‰¤ 19 mcg), baculovirus and cellular DNA (â‰¤ 
10 ng), and Triton X -100 (â‰¤ 100 mcg)  
 Route:  Liquid/Intramuscular injection (0.5 mL)  
  
Licensed Study Product 2 : To be determined prior to each influenza season  
 Form:  Single 0.5 mL dose  
 Composition:  â€¢ 15 mcg HA of each of influenza types and subtypes A (H1N1), A 
(H3N2), and one or two B lineages (trivalent or quadrivalent, 
respectively, of B/Yamagata and/or B/Victoria)  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 8 of 43 â€¢ Additional composition details will vary, determined by [CONTACT_669494]:  Liquid/Intramuscular injection (0.5 mL)  
   
Inclusion Criteria:  Adults [ADDRESS_904145] dose inactivated 
influenza vaccine during the 2018-2019,  2019-2020, and 2020-2021  
influenza seasons be determined prior to each influenza season 
Exclusion Criteria:  Adults 18 -64 years who do not receive Flublok or SD -IIV during the 2018-
2019,  2019-2020 , and/or 2020-2021  influenza seasons  
Statistical Methods:  â€¢ The relative vaccine effectiveness will be calculated based on the 
formula rVE = 1 â€“ relative Hazard Ratio (rHR), where rHR is estimated 
from a fully adjusted Cox Regression model (further described in 
Section 11.1).  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 9 of 43 Table of Study  Procedures  
Not applicable.  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904146]  Randomized Control Trial  
RR Relative Risk 
rVE Relative Vaccine Effectiveness  
SAE  Serious Adverse Event  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Event  
VAERS  Vaccine Adverse Event Reporting System  
VE Vaccine Effectiveness  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 11 of 43 1 Introduction  
1.1 Background  
Influenza viruses types A and B belong to the genus Orthomyxoviridae and are characterized as 
enveloped, negative -strand, segmented r ibonucleic acid (RNA ) viruses. The viral envelope 
contains 2 virus -coded glycoprotein spi[INVESTIGATOR_2988], the hemagglutinin (HA) and neuraminidase (NA) 
proteins, which are key antigens in the host response to influenza virus in both natural 
infection  and vaccination. A third protein, M2, is a minor envelope component of the A -strain 
viruses.  
Influenza is transmitted through inhalation of virus -containing droplets from infected individuals. 
The incubation period is usually [ADDRESS_904147] before illness onset (within 24 hours), rapi[INVESTIGATOR_190562], and remains elevated for 1 to 2 days before rapi[INVESTIGATOR_644212]. Usually, virus shedding 
lasts a total of 5 to 10 days.  
There is considerable variation in the severity of illness in different individuals, partly due to age, general health, and immune status relative to previous influenza infections  and vaccination . The 
classic symptoms include rapid onset (12 hours or less) of malaise, fever, myalgia, headache, and a non- productive cough or sore throat. Most symptoms last several days, but malaise and cough 
may last for a week or more. Complications of i nfluenza include primary viral pneumonia, 
secondary bacterial pneumonia, and exacerbation of underlying medical conditions such as 
chronic obstructive pulmonary disease and congestive heart failure.  
While influenza affects all age groups, seniors , childre n younger than 5 years of age,  and persons 
with underlying health problems are at increased risk for complications. Members of high- risk 
groups who become ill with influenza are more likely than the general population to require hospi[INVESTIGATOR_669480] (e.g., pneumonia and cardiovascular events) . 
Groups considered at higher risk for influenza -related complications includ e persons aged â‰¥65 
years  due to immunosenescence and a dults 50â€“[ADDRESS_904148] to continuous and sequential evolution within  immune or partially immune 
populations. Antigenic drift results from mutation(s) affecting the RNA segment coding for either HA or NA, but more commonly HA. As a result, there is alteration in protein structure involving 
1 or a few amino acids, resulting in minor changes in antigenicity. Antigenic variants within a 
subtype (e.g., H1 or H3) emerge and through natural selection gradually become the more predominant circulating virus strain, while the preceding antigenic variant is suppressed by 
[CONTACT_669495]. In contrast to antigenic drift, antigenic shift represents the 
emergence of completely new subtypes, typi[INVESTIGATOR_644214]. Antigenic shift 
occurs at irregular intervals and may lead to pandemics. While influenza B appears to be more 
genetically stable than influenza A, the dominant circulating B strain typi[INVESTIGATOR_669481]. For over a decade, both Yamagata and Vic toria lineages have co -circulated during each 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904149] the other. Accordingly, switching from a trivalent vaccine to a quadrivalent 
vaccine is expected to prevent additional morbidity and mortality associated with mismatched 
influenza B strains that may occur with trivalent vaccines. With this in mind, Flublok 
Quadrivalent vaccine w ere developed.  
Vaccination with influenza vaccine is the primary method for preventing influenza and its severe complications. It has been shown to be effective in reducing influenza- associated morbidity and 
mortality in groups at increased risk for influenza- related complications such as infants and young 
children  and persons 50 years of age and older.  Of note , immune responses to the vaccine are 
lower in seniors than those in young healthy adults. Strategies to improve immune r esponses to 
the vaccine in the elderly population could provide significant additional reductions in influenza -
associated morbidity and mortality. One approach is to increase the dose of HA in vaccines. Previous studies evaluating the immune responses in t erms of hemagglutination inhibition (HAI) 
antibodies with higher doses of HA per strain in different influenza vaccines support a dose -
response effect.  
Flublok Quadrivalent vaccine is a recombinant HA influenza vaccine indicated for active immunization aga inst disease caused by [CONTACT_14302] A subtype viruses and type B viruses contained 
in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza 
viruses in embryonated henâ€™s eggs. Recombinant technology also allows control over the 
sequence of the full -length HA produced. The recombinant proteins are highly purified and the 
vaccine contain s no egg protein, preservatives , or antibiotics, a ny of which may produce 
hypersensitivity reaction in some individuals.  
Flublok Quadrivalent vaccine contains [ADDRESS_904150] -dose inactivated quadrivalent influenza vaccine ( SD-IIV4 ). The hi gh 
purity of a recombinant antigen enables administration of a  higher concentration of HA antigen  
without a n increase in adverse effects in humans. This higher dose of antigen may be a particular 
advantage to older adults whose immune responses to influenz a vaccines can be suboptimal.  
During this study, Flublok Quadrivalent or SD -IIV will be administered according to the 
guidelines in the Prescribing Information materials and only to persons for whom it is indicated. 
The 2018â€“2019, 2019â€“2020, and 2020â€“2021  formulations of recombinant influenza vaccine 
(Flublok
 Quadrivalent  vaccine)  and SD -IIV will be evaluated as described below.  
The overall objective of this study is to describe the effectiveness  of Flublok Quadrivalent vaccine 
compared to SD -IIV in adults 18 through 64 years of age.  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904151] 
Previous Clinical Experience: Flublok Vaccine  
Flublok vaccine (trivalent formulation) was first approved in the [LOCATION_002] on 16 January 
2013 for use in adults 18â€“49 years of age. Licensure was bas ed on results of a randomized 
controlled efficacy trial of Flublok vs placebo in 2344 subjects. The age indication was expanded to include all adults 18 years of age and older in 2014 based on safety and immunogenicity data 
from 2 studies; the first was co nducted among 869 adults 65 years of age and older and the second 
was conducted among 602 adults 50â€“64 years of age.  
Flublok Quadrivalent Vaccine  
On 07 October 2016, the FDA licensed Flublok Quadrivalent vaccine for adults 18 years of age and older. This a pproval was based on 2 studies conducted during the 2014â€“2015 influenza 
season: (1)  an immunogenicity and safety study of Flublok Quadrivalent vaccine versus SD -IIV4 
in 1350 adults 18â€“49 years of age and (2) an efficacy, immunogenicity, and safety study of  
Flublok Quadrivalent vaccine versus SD -IIV4 in 9003 adults 50 years of age and older. In the 
former study (of adults 18â€“49 years of age), immunogenicity of Flublok Quadrivalent vaccine 
was non- inferior to that of the SD -IIV4 comparator for 3 of the 4 anti gens; the response to the B 
Victoria lineage strain did not meet the non- inferiority criteria but the response was low in both 
vaccine groups, making comparisons uninterpretable. In the latter efficacy study of adults 50 
years of age and older, Flublok Qua drivalent vaccine, compared to the SD -IIV4 comparator, 
demonstrated 30% to 43% greater efficacy in preventing laboratory- confirmed, protocol -defined 
influenza -like-illness caused by [CONTACT_654754].  
The most common local adverse reactions (ARs) to Flublok Quadrivalent vaccine include 
tenderness and pain at the injection site. The most common systemic reactions include headache, 
fatigue, myalgia, and arthralgia , with most events being mild to moderate in severity. Safety 
profiles of Flublok influenza vaccine and inactivated influenza vaccine (trivalent and quadrivalent 
comparisons) were demonstrated to be similar in clinical trials.  
1.3 Potential Benefits and Risks 
1.3.1 Potential  Benefits to Subjects  
Not applicable. This is not clinical trial. T he pre sent study is a prospective study using EMR data 
that are collected as part of routine clinical care.  
1.3.2 Potential  Risks to Subjects  
Not applicable. This is not clinical trial. T he present study is a prospective study using EMR data 
that are collected as part  of routine clinical care.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904152] on 
public health.  In an efficacy, immunogenicity, and safety study of Flublok Quadrivalent vaccine 
versus SD -IIV4 among 9,003 adults 50 years of age and older, Flublok Quadrivalent vaccine, 
compared to SD -IIV4, demonstrated 30% to 43% greater efficacy in preventing laboratory-
confirmed, protocol -defined influenza -like-illness caused by [CONTACT_654754].  
According to the Centers for Disease Control and Prevention, recombinant  technology potentially 
offers additional  flexibility over egg - and cell -propagated vaccines . Flublok Quadrivalent vaccine  
is specifically manufactured to achieve an exact genetic match to the HA of each influenza strain 
selected by [CONTACT_669496].  In addition, recombinant -based influenza 
vaccines have the promising  benefit to offer better protection  by [CONTACT_669497]-  and cell -propagated influenza vaccines . The primary objective of 
the current study is to evaluate the relative vaccine effectiveness ( rVE) of Flublok Quadrivalent 
vaccine compared to SD -IIV. 
2 Study  Objectives  
2.1 Primary Objective  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904153] all PCR -confirmed influenza.  
The endpoint for the primary objective is presented in Section  9.1.4 . 
2.2 Secondary Objectives  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904154] PCR -confirmed hospi[INVESTIGATOR_669477].  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904155] hospi[INVESTIGATOR_669478] -acquired pneumonia.  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904156] hospi[INVESTIGATOR_669482] -respi[INVESTIGATOR_669483] (e.g., pneumonia, other 
lower respi[INVESTIGATOR_18073], acute myocardial infarction, congestive heart failure, stroke).  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees ag ed 50â€“
[ADDRESS_904157] PCR- confirmed influenza A .  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904158] PCR- confirmed influenza B .  
â€¢ Sub- analyses of the above outcomes as feasible by [CONTACT_669498] -exist ing conditions:  
1. Cardiovascular preexisting conditions composite , which may include : 
myocardial infarction, cerebrovascular accident, atrial fibrillation, arrhythmias, 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 15 of 43 coronary artery disease, valvular heart disease/valvuloplasty, chronic/congestive 
heart failure and/or congenital heart defects, CABG, angioplasty/stents, 
cardioversion, pacemaker, implantable cardioverter defibrillator, LVAD, heart 
transplant, hypertensive disease 
2. Respi[INVESTIGATOR_669484], which may include:  COPD 
and/or pulmonary HTN  
3. Cardiorespi[INVESTIGATOR_669484]: combined pre -existing 
conditions (a) and (b) above  
4. Obesity:  based on available height/weight data for a  calculated BMI â‰¥30 or an 
obesity diagnosis (e.g., ICD -10 E66.9)  
5. Diabetes:  based on a diagnosis of diabetes  
 
The endpoint (s) for the secondary objective(s) are presented in Section  9.2.4.  
2.3 Exploratory Objectives  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904159] exploratory outcomes such as:  
a. Diagnosed with influenza (includes [1] adults with a PCR -positive influenza and 
[2] adults clinically -diagnosed with influenza in any setting but not tes ted); this 
outcome will exclude those with a clinically -diagnosed influenza but are tested and 
PCR- negative)  
b. All-cause hospi[INVESTIGATOR_602]  
c. All-cause mortality  
 
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in other age ranges of 
vaccinees  â€” aged 18â€“64 years and aged 18â€“49 years â€” against outcomes such as (but not 
limited to):  
a. All PCR -confirmed influenza  
b. All PCR -confirmed influenza A and influenza B (separate rVE estimates)  
c. PCR- confirmed hospi[INVESTIGATOR_669485]  
d. Hospi[INVESTIGATOR_669478] -acquir ed pneumonia  
e. Hospi[INVESTIGATOR_669482] -respi[INVESTIGATOR_669483] 
f. All-cause hospi[INVESTIGATOR_059]  
g. All-cause mortality  
 
â€¢ Sub- analyses of the primary and secondary outcomes of sub- groups defined by [CONTACT_094] -
existing conditions (as described above in Section 2.2) will be conducted among adults 
18â€“49 years as feasible  
 
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus SD -IIV among adults aged 
18â€“64 years for PCR -confirmed influenza A subtypes (A(H1N1)pdm09 and A(H3)) and 
lineage for type B influenza (B/Victoria, B/Yamagata) as feasible 
 
The endpoint (s) for the observational objective(s) are presented in Secti on 9.3.4.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 16 of 43 3 Investigators and Study  Organization  
This study will be conducted at Kaiser Permanente Northern [LOCATION_004] (KPNC ), which is an 
integrated health care system with a membership population of approximately 4 million in 2018, 
including approximately 2.5 million adults between 18 to 64 years of age. The eligible population 
for this study include s all persons 18 to 64 years of age . KPNC m embers receive nearly all their 
care at KPNC facilities, which includes  approximately 65 medical clinics and 2 7 hospi[INVESTIGATOR_600]. 
Diagnoses, laboratory tests, vaccines, and medications are all captured in KPNCâ€™s  electronic 
medical record (EMR) and clinical databases.  
4 Independent Ethics Committee  / Institutional Review Board  
Kaiser Permanente Vaccine Study Center (KPVSC) received IRB approval on April 3, 2018, to 
conduct the following prospective randomized observational study: â€œExamining vaccine 
effectiveness (VE) of Flublok Quadrivalent (Influenza Vaccine) relative to standard dose 
inactivat ed influenza vaccine among Kaiser Permanente Northern [LOCATION_004] members aged 18 -64 
years ([COMPANY_011] Pasteur).â€  
Because the present study is a prospective study using EMR data that are collected as part of 
routine clinical care , no informed consent will be  required. Protected Health Information (PHI) 
will be used by [CONTACT_669499] (i.e., Principal Investigator, Statistician, Data Manager, Data 
Analysts, Project Manager), but no PHI will be made available to anyone outside of KPVSC. All 
data reported to [COMPANY_011]  Pasteur  will be  de-identified in accordance with Health Insurance 
Portability and Accountability Act of 1996  (HIPAA ). Further, no individual -level data will be 
reported to [COMPANY_011] Pasteur . 
[ADDRESS_904160] all PCR -confirmed 
influenza  in vaccinees aged 18â€“64 years, this study will  compare the incidence of PCR -confirmed 
influe nza among Flublok Quadrivalent vaccinees versus SD -IIV vaccinees . Our primary 
comparison will be focused on adults aged 50â€“64 years at KPNC during the 2018â€“2019 , 2019â€“
2020, and 2020â€“2021  influenza seasons. We will also assess all adults aged 18 â€“64 years for both 
influenza seasons .  
5.1.2 Justification of the Study  Design  
Please refer to Section 11 .1 for details.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 17 of 43 5.1.3 Study  Plan  
This study will employ a design whereby [CONTACT_669500]-IIV. All KPNC facilities will follow 
a schedule that alternates which vaccine is supplied to each in fluenza clinic throughout the 3- year 
study period.  
We will block facilities and randomize within blocks  (see Section 5.1.4 ), ensuring that roughly 
half the facilities within each block initially administer Flublok Quadrivalent vaccine and the 
other half a dminister a SD-IIV. After the initial supply, the half that started with Flublok 
Quadrivalent vaccine will be supplied with a SD-IIV, and the half that started with a SD-IIV will 
be supplied with Flublok  Quadrivalent vaccine (see Figure 1 ). The supply of e ach clinic will then 
alternate between the two vaccines; that is, Flublok Quadrivalent vaccine alternating with a SD-
IIV with each delivery of vaccine to the clinics .  
  
 
Data Extraction  
Pertinent d ata will be extracted from the KPNC databases to create study datasets in the required 
file format for analysis (e.g., Excel spreadsheets, SAS datasets). Databases from which data will 
be extracted include various encounters (inpatient, outpatient, hospi[INVESTIGATOR_602], emergency 
department, etc.), laborator y tests, documentation of immunizations (e.g., influenza vaccination 
history), and clinical outcomes and diagnoses, as well as demographic and membership data.  
The data analyst will perform validation of the study data throughout the data management 
proces s by [CONTACT_669501]:  
â€¢ Internal consistency checks (e.g. data undergo range checks, including consistency of 
dates of birth with vaccination dates, checks for completeness and missing values, etc.)  
â€¢ External data checks  (e.g. data from one database may be compared with data from other 
databases)  
â€¢ Error checks written for specific databases.  

Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 18 of 43 5.1.4 Vaccin e Distribution  Procedures  
Based on prior annual influenza vaccine use, we anticipate that KPNC will administer influenza 
vaccin es to approximately 800,000 individuals aged 18â€“64 years, including 350,000 persons  aged 
50â€“64 years  each season . 
Approximately 400,000 doses of Flublok Quadrivalent vaccine and 400,000 doses of comparator  
SD-IIV will be administered to adults aged 18â€“64 years in each of the influenza seasons 2018â€“
2019, 2019â€“2020 , and 2020â€“2021 .  
There are approximately 70 facilities that receive individual influenza vaccine shipments from the KPNC Central Pharmacy (the exact number varies slightly each year ; see Figure 2  for an example 
of the flow). KPNC Central Pharmacy begins â€œautoshipmentsâ€ to the Medical Centers and their 
satellite facilitiesâ€™ main pharmacies in August in preparation for annual influenza vaccination 
clinics. For purposes of this study, medical  center facilities include all associated satellite sites. 
KPNC Central Pharmacy determines the amount of vaccines to be shipped each day to the medical center facilities based upon vaccine use the previous year at each facility. For example, 
since Oakland  Medical Center administered ~5% of all vaccines during the 2017â€“2018 influenza 
season, they would receive 5% of the daily shipment of vaccines during the subsequent 2018â€“[ADDRESS_904161] additional vaccine as needed.  
 
Once the facilities receive adequate influenza vaccines to distribute to all of  their influenza 
vaccination clinics, they will prepare vaccine allotments for specific patient populations within each clinic (e.g., adult medicine, OB/GYN). We propose to random ize these facilities to distribute 
(and therefore administer ) either Flublok Quadrivalent vaccine or a SD-IIV initially  to all of their 
influenza vaccination clinics . Roughly half the facilities will first distribute Flublok Quadrivalent 
vaccine to be admi nistered by  [CONTACT_669502], while the other half will 
first distribute a SD-IIV for administration by [CONTACT_669502] . The 
facilities will follow a weekly alternating schedule  (with some variation due to u sage)  that 
indicates which vaccine is to be internally distributed to associated departments and clinics for the entire influenza season. Historically, >75% of vaccinations to adults aged 18â€“64 are administered 
prior to Thanksgiving.  

Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904162] (see Section 1 1.1 for further details).  
In order to randomize which facilities will initially administer Flublok Quadrivalent vaccine and 
which will start with a SD-IIV, we will block facilities by [CONTACT_669503]. For example, 
there may be 4 facilities per block, and within the block, 2 facilities start with Flublok Quadrivalent vaccine and 2 facilities start with a SD-IIV.  
Staff Training: Pharmacy Staff, Influenza Clinic Injection Nurses , and Nurse Managers  
KPVSC will work closely with the KPNC Central Pharmacy, the KPNC influenza program 
manager, the pharmacy staff , and influenza coordinators at the ~[ADDRESS_904163] trainings with the pharmacy staff, influenza coordinators, and department managers so that all relevant staff 
are aware that Flublok Quadrivalent vaccine or a SD-IIV should be routinely administered to 
everyone 18â€“64 years of age without any preference for one vaccine over the other, and that vaccine use should be based only on what is available in the clinic at the time of vaccination.  
In particular, we will emphasize that the injection nurse administering the vaccine should not preferentially choose one vaccine over the other, but instead use wha t is available in the 
refrigerator or portable cold storage box for the day. Based on routine influenza clinic operations, there is little potential for bias at the level of vaccine administration level  (e.g., an injection nurse 
preferentially choosing one  vaccine over the other) , especially early in the season, when large 
numbers of influenza vaccine are administered on any given day ; injection nurses are unlikely to 
spend time searching for a specific formulation based on preference. Further, by [CONTACT_669504], we will reduce the likelihood that both Flublok Quadrivalent 
vaccine and SD-IIV are simultaneously available in the clinic . By [CONTACT_669505] 18 â€“64 years (Flublok Quadrivalent vaccine or SD-IIV), we hope to 
reduce the likelihood that an injection nurse is able to choose one vaccine over the other.  
Because influenza vaccine is used at a very rapid pace once influenza clinics officially begin 
administering vaccine, the departments and clinics may request vaccine replenishment prior to the 
next distribution in order to ensure adequate supply. For this reason, it may be possible that a 
particular clinic will have both Flublok Quadrivalent vaccine and a SD-IIV available.  
On a weekly ba sis, we will also monitor both the distribution of vaccine from KPNC Central 
Pharmacy to the facility pharmacies, as well as influenza vaccine administration. If we detect  
imbalances  at either of these points, we will work closely with the affected facility(s) to attempt to 
correct the imbalance. Additional details may be found in Section  11.1. 
5.1.[ADDRESS_904164] Flublok Quadrivalent vaccine or SD-IIV vaccine(s) . 
Planned study period (total) : August 2018 to May 2022  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904165] study member influenza vaccination date: September 16, 2018  
Planned vaccination periods: August [ADDRESS_904166] 
2020 to April  2021  
Planned date of draft study report: February 2022  
Planned date of final study report: May 2022  
5.2 Study  Population  
5.2.1 Recruitment Procedures  
Eligible adults aged 18â€“[ADDRESS_904167] fulfill all of the following criteria to be eligible for the study:  
â€¢ Between the ages of â‰¥ 18 and <65  years at the time of influenza vaccination  
â€¢ Receive either Flublok Quadrivalent vaccine or SD-IIV at a KPNC f acility during the 
study period from August 2018 through April 202 1 
5.2.5 Exclusion Criteria  
An individual fulfilling any of the following criteria is to be excluded from the study to the extent 
possible:  
â€¢ Children <18 years old  
â€¢ Adults â‰¥65 years old 
5.2.6 Medical Histo ry 
Prior to receiving an influenza vaccination (either Flublok Quadrivalent vaccine or SD-IIV), 
patients will be screened using a n influenza vaccination screening form as part of a routine pre-
vaccination assessment.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904168] adequate follow -up times .  
5.2.9 Follow -up of Discontinuations  
Not applicable.  
5.2.10  Follow -up and Reporting of Pregnancies  
We will include  KPNC members who receive Flublok Quadrivalent vaccine or SD-IIV vaccine(s)  
while aged 18â€“[ADDRESS_904169] (for influenza) per influenza season, and only if it is â‰¥14 days 
after vaccination , and follow -up will  continue either through April 30 of each influenza season or 
until exit from KPNC, whichever occurs earlier. In the KPNC system, influenza PCR tests are used for clinical purposes, thus the â€œtriggerâ€ for an influenza PCR test is based on clinical 
presentation. The decision to test is up to each physician. KPNC al so monitors the influenza 
season, which can affect the total amount of influenza testing at any point in the season.  
Pregnancy is not an exclusion criterion for this study. Patients who are â‰¥[ADDRESS_904170] the earlier version. Any substantial amendments (e.g., those that affect the conduct of the study, the safety of the subjects, 
or the analysis of the data)  require KPNC IRB approval.  
During the period for which KPNC IRB approval has already been given, KPVSC is responsible for ensuring that changes to an approved study are not initiated without KPNC IRB review and 
approval, except as needed to eliminate app arent immediate hazards to subjects.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 22 of 43 5.4 Interruption of the Study  
The study may be discontinued if data about Flublok Quadrivalent vaccine or comparator 
resulting from this or any other studies become available; or for administrative reasons; or on 
advice of [COMPANY_011] Pasteur, KPVSC, the KPNC IRB, or the governing regulatory authorities in the 
US where the study is taking place.  
If the study is prematurely terminated or suspected, [COMPANY_011] Pasteur shall promptly inform KPVSC, the KPNC IRB, and the regulatory author ities of the reason for termination or suspension, as 
specified by [CONTACT_1214]. If applicable, KPNC will follow internal protocols for notifying patients who may have received Flublok in the course of routine patient 
care.  
[ADDRESS_904171](s)  
6.1.[ADDRESS_904172](s)  
Flublok Quadrivalent vaccine is indicated for active immunization against disease caused by 
[CONTACT_14302] A subtype  viruses  and influenza type B virus es contained in the vaccine. Flublok 
Quadrivalent vaccine is a sterile solution  supplied in prefilled , single -dose syringes , 0.5 mL .  
[IP_ADDRESS]  Composition  
Flublok Quadrivalent vaccine is formulated to contain 180 mcg HA per 0.5 mL dose with 45 mcg 
HA of each of the following influenza type s and subtype s: A (H1N1), A (H3N2), and two B 
lineages (B/Yamagata and B/Victoria).  
A single 0.5 mL dose of Flublok Quadrivalent vaccine contains sodium chloride (4.4 mg), 
monobasic sodium phosphate (0.195 mcg), dibasic sodium phosphate (1.3  mg), and polysorbate 
20 (TweenÂ®20) (27.5  mcg). Each 0.5mL dose of Flublok Quadrivalent vaccine may also contain 
residual amounts of baculovirus and Spodoptera frugiperda cell proteins (â‰¤  19 mcg), baculovirus 
and cellular DNA (â‰¤  10 ng), and Triton X -100 (â‰¤  100 mcg).  
Flublok Quadrivalent vaccine contains no egg proteins, antibiotics, or preservatives.  The single -
dose, pre -filled syringes contain no natural rubber latex.  
[IP_ADDRESS]  Preparation and Administration  
Prior to administration, all Flublok Quadrivalent vaccine must be inspected visually for cracks, broken seals, correct label content , and extraneous particulate matter and/or discoloration, 
whenever solution and container permit . If any of these conditions exist, the vaccine must not be 
administered  and another dose of Flublok Quadrivalent vaccine is to be used, and the event is to 
be reported to [COMPANY_011] Pasteur.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 23 of 43 To administer the vaccine, invert the pre -filled syringe containing Flublok Quadrivalent vaccine 
gently prior to affixing the appropriate size needle for intramuscular administration. The preferred 
site for injection is the deltoid muscle. Flublok Quadriva lent vaccine should not be mixed in the 
same syringe with any other vaccine.  
[IP_ADDRESS]  Dose Selection and Timing  
Not applicable.  
6.1.[ADDRESS_904173](s)   
SD-IIV is defined as all standard -dose quadrivalent inactivated egg- based influenza vaccines  
administered intramuscularly during the course of this study in KPNC facilities.  
The comparator  SD-IIV vaccine(s) that will be used each year is determined and ordered at the 
national KP level ; thus KPVSC does not have influence over what comparator  SD-IIV vaccine( s) 
are purchase d.  KPVSC will be notified of which comparator vaccine will be used within KPNC. 
The comparator influenza vaccine(s) will be acquired through national KPâ€™s usual procurement 
processes.  
[IP_ADDRESS]  Composition  
Comparator SD-IIV influenza vaccine(s)  will be used, as determined by [CONTACT_669506].  
SD-IIV vaccine( s) are formulated to contain 15  mcg HA or 60 mcg HA (trivalent or quadrivalent 
formulation, respectively) per 0.5 mL dose with 15 mcg HA of each of the following influenza 
types and subtypes: A (H1N1), A (H3N2), and one or two B lineages ( trivalent or quadrivalent 
formulation, respectively; trivalent will contain either a B/Yamagata or B/Victoria  strain as per 
FDA guidance ). The specific final formulation will be dependent on comparator SD -IIV 
vaccine(s) that will be ordered and used each year as determined at the national KP level.  
[IP_ADDRESS]  Preparation and Administration  
The procedures for preparing and administering t he comparator  SD-IIV influenza vaccine(s) will 
be prepa red and administered as per the manufacturerâ€™s package insert.  
[IP_ADDRESS]  Dose Selection and Timing  
Not applicable.  
6.[ADDRESS_904174](s) 
Not applicable.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904175] Logistics  
6.3.1 Labeling and Packaging  
All vaccines will be supplied with their manufacturerâ€™s commercia l labeling and packaging.  
6.3.[ADDRESS_904176] Shipment, Storage, and Accountability  
[IP_ADDRESS]  Product Shipment  
[COMPANY_011] Pasteur will contact [CONTACT_29517] a designee to determine the dates and times of 
delivery of products.  
Each vaccine shipment will include a temperature- monitoring device to verify maintenance of the 
cold chain during transit. On delivery of the product to the site, the person in charge of product 
receipt will follow the instructions given in the Operating Guidelines, including checking that the 
cold chain  was maintained during shipment (i.e., verification of the temperature recorders). If 
there is an indication that the cold chain was broken, this person should immediately quarantine the product, alert the [COMPANY_011] Pasteur  representative, and request authori zation from [COMPANY_011] Pasteur  
to use the product.  
[IP_ADDRESS]  Product Storage  
All temperature monitoring, including storage and shipment within KPNC sites, of Flublok Quadrivalent vaccine,  will be per KPNC pharmacyâ€™s internal standard operating procedures. 
KPVSC itself w ill not directly monitor nor manage temperature excursions if they arise.  
Any excursion of temperature during the initial shipment of Flublok Quadrivalent vaccine 
performed by [CONTACT_669507] a full evaluation and shall be documented, reviewed, 
and approved by [CONTACT_35346] /Protein Sciences  in accordance with its internal procedures. If 
there is a temperature excursion, KPNC must quarantine the clinical supply until the [COMPANY_011] 
Pasteur evaluation is complete.  
Any excursion of temperature during storage or shipment performed by [CONTACT_669508] a full 
evaluation by [CONTACT_669509] , and shall be documented, reviewed, and approved by [CONTACT_669510]. If KPNC requests additional evaluation needed for decision  making from [COMPANY_011] Pasteur, [COMPANY_011] Pasteur will provide assistance in accordance with 
its internal procedures.  
[IP_ADDRESS]  Product Accountability  
When patients receive Flublok Quadrivalent vaccine (or SD-IIV), the vaccine administrator will 
record the vaccination information into their medical record, including the formulation, dose, lot 
number, and date of vaccination.  
6.3.[ADDRESS_904177] [COMPANY_011] Pasteur to resolve as appropriate.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904178] of the study.  
6.4 Blinding and Code-breaking Procedures  
Not applicable.  
6.5 Randomization and Allocation Procedures  
Subjects will not be individually randomized . A modified- cluster randomization scheme by  
[CONTACT_669511] . 
This study will employ a design whereby [CONTACT_669512] -IIV. All KPNC facilities will 
follow a schedule that alternates which vaccine is supplied to each influenza clinic throughout the 3-year season period.  
We will block facilities and randomize within blocks (see Section 5.1.4 ), ensuring that roughly 
half the facilities within each block initially administer Flublok Quadrivalent vaccine and the 
other half administer a SD -IIV. After the initial supply, the half that started with Flublok 
Quadrivalent vaccine will be supplied with the SD -IIV, and the half that started with SD -IIV will 
be supplied with Flublok Quadrivalent vaccine (see Figure 1 ). The supply of each clinic will then 
alternate between the two vaccines; that is, Flublok Quadrivalent vaccine alternating with SD -IIV 
with each delivery of vaccine to the clinics .  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 26 of 43    
6.6 Vaccine Administration Compliance  
The following measures will ensure that the vaccine doses administered comply with those planned, 
and that any non- compliance is documented so that it can be accounted for in the data analyses:  
â€¢ All vaccinations will be administered by [CONTACT_669513]  
â€¢ The person in charge of product management at the site will maintain accountability records 
of product delivery to the study  site as per KP NC standard  operating procedures  
6.7 Concomitant Medications and Other Therapi[INVESTIGATOR_149947].  
7 Management of Samples  
Not applicable.  
8 Endpoints and Assessment Methods  
8.1 Primary Endpoints and Assessment Methods 
8.1.1 Relative Vaccine Effectiveness of Flublok  Quadrivalent vaccine  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904179] all PCR -confirmed influenza.  
 

Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 27 of 43 The rVE will be calculated based on the following formula:  
ð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿ  =1âˆ’ð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿ ð»ð» ð‘Ÿð‘Ÿð»ð»ð‘Ÿð‘Ÿð‘Ÿð‘Ÿð»ð» ð‘…ð‘…ð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Žð‘Ž  (ð‘Ÿð‘Ÿð»ð»ð‘…ð‘…) 
where rHR is estimated  from the fully adjusted Cox Regression model ( described in Section 
11.1) . 
Diagnoses, laboratory tests, vaccines, and medications are all captured in the electronic medical 
record (EMR) and clinical databases . Member -reported race/ethnicity is available for 
approximately 85% of members, while the remaining are imputed using the R AND BISG 
algorithm .  
All microbiological testing is conducted at  KPNC laborator ies that have used real-time PCR tests 
for influenza since 2006.  PCR results are categorized as positive for  influenza A ; positive for 
influenza B ; or ne gative for both . In the KPNC system, influenza PCR test s are used for clinical 
purpose s, thus the "trigger" for a n influenza PCR test is based on clinical presentation. The 
decision to test is up to each physician.  KPNC  monitor s the influenza season which can affect the 
total amo unt of influenza testing  in adults . Once the KPNC laboratories complete the PCR testing, 
the test result is updated in the patientâ€™s EMR.  
The majority of KPNCâ€™s  influenza cases are seen  in the outpatient setting. Most of the remaining 
cases  are treated in the ED  with a very small portion admitted to hospi[INVESTIGATOR_669486] 5.1.1 for details pertaining to th e assessment  of rVE . 
8.2 Secondary Endpoints and Assessment Methods 
8.2.1 Relative Vaccine Effectiveness of Flublok  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904180] PCR -confirmed hospi[INVESTIGATOR_669477].  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904181] hospi[INVESTIGATOR_669478] -acquired pneumonia.  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904182] hospi[INVESTIGATOR_669482] -respi[INVESTIGATOR_669483] (e.g., pneumonia, other 
lower respi[INVESTIGATOR_18073], acute myocardial inf arction, congestive heart failure, stroke).  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904183] PCR- confirmed influenza A .  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50â€“
[ADDRESS_904184] PCR- confirmed influenza B .  
â€¢ Sub- analyses of the above outcomes as feasible by [CONTACT_669498] -existing conditions:  
6. Cardiovascular preexisting conditions composite , which may include : 
myocardial infarction, cerebrovascular accident, atrial fibrillation, arrhythmias, coronary artery disease, valvular heart disease/valvuloplasty, chronic/congestive 
heart failure and/or congenital heart defects, CABG, angioplasty/stents, 
cardioversion, pac emaker, implantable cardioverter defibrillator, LVAD, heart 
transplant, hypertensive disease  
7. Respi[INVESTIGATOR_669484], which may include:  COPD 
and/or pulmonary HTN  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 28 of 43 8. Cardiorespi[INVESTIGATOR_669484]: combined pre -existing 
conditions (a) and (b) above  
9. Obesity:  based on available height/weight data for a calculated BMI â‰¥30 or an 
obesity diagnosis (e.g., ICD -10 E66.9)  
10. Diabetes:  based on a diagnosis of di abetes  
 
The rVE will be calculated based on the following formula:  
ð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿ  =1âˆ’ð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿ ð»ð» ð‘Ÿð‘Ÿð»ð»ð‘Ÿð‘Ÿð‘Ÿð‘Ÿð»ð» ð‘…ð‘…ð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Ÿð‘Žð‘Ž  (ð‘Ÿð‘Ÿð»ð»ð‘…ð‘…) 
where rHR is estimated from the fully adjusted Cox Regression model ( described in Section 
11.1) . 
Data on the secondary endpoints will be extracted from the KPNC databases that contain 
encounters on patient hospi[INVESTIGATOR_602]. ICD -10 codes will be extracted based on the discharge 
diagnoses recorded in the patientsâ€™ EMR. The specific codes used to identify community- acquired 
pneumonia a nd cardio- respi[INVESTIGATOR_669487].  
 Please refer to Section 8.1 .1 for details pertaining to PCR assessment , and Section 5.1.1 for details 
pertaining to the  assessment  of rVE . 
8.3 Exploratory Endpoints and Assessment Methods  
8.3.1 Relative Vaccine Effectiveness of Flublok  
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in vaccinees aged 50 â€“
[ADDRESS_904185] exploratory outcomes such as:  
a. Diagnosed with influenza (includes [1] adults with a PCR -positive influenza and 
[2] adults clinically -diagnosed with influenza in any setting but not tested); this 
outcome will exclude those with a clinically -diagnosed influenza but are tested and 
PCR- negative)  
b. All-cause hospi[INVESTIGATOR_602]  
c. All-cause mortality  
 
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus  SD-IIV in other age ranges of 
vaccinees â€” aged 18â€“64 years and aged 18â€“49 years â€” against outcomes such as (but not 
limited to):  
a. All PCR -confirmed influenza  
b. All PCR -confirmed influenza A and influenza B (separate rVE estimates)  
c. PCR- confirmed hospi[INVESTIGATOR_669485]  
d. Hospi[INVESTIGATOR_669478] -acquired pneumonia  
e. Hospi[INVESTIGATOR_669482] -respi[INVESTIGATOR_669483] 
f. All-cause hospi[INVESTIGATOR_059]  
g. All-cause mortality  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 29 of 43 â€¢ Sub- analyses of the primary and secondary outcomes of sub- groups defined by [CONTACT_094] -
existing conditions (as described above in Section 2.2) will be conducted among adults 
18â€“49 years as feasible  
 
â€¢ To estimate the rVE of Flublok Quadrivalent vaccine versus SD -IIV a mong adults aged 
18â€“64 years for PCR -confirmed influenza A subtypes (A(H1N1)pdm09 and A(H3)) and 
lineage for type B influenza (B/Victoria, B/Yamagata) as feasible 
 Data on the exploratory endpoints will be extracted from the KPNC databases that contain 
relevant encounters on patient hospi[INVESTIGATOR_192354]. ICD -10 codes will be extracted 
based on the dischar ge diagnoses recorded in the patientsâ€™ EMR. The specific codes used to 
identify diagnoses of interest will be further specified in the SAP.  
  
Please refer to Section 8.1.1 for details pertaining to PCR assessment, and Section 5.1.1 for details 
pertaining t o the assessment of rVE.  
9 Reporting of Serious Adverse Events   
9.1 Initial Reporting by [CONTACT_669514] (see 21 CFR 314.80) that may be related to Flublok, 
including any follow -up information,  will be reported promptly to [COMPANY_011] Pasteur , national 
regulatory authorities (e.g., to the Vaccine Adverse Event Reporting System [VAERS]), and the KPNC Institutional Review Board, in accord with any applicable requirements.  
 KPVSC will perform the study in compliance with all applicable local and international 
pharmacovigilance laws and regulations. Although the conduct of the study is entirely the responsibility of KPVSC, [COMPANY_011] Pasteur /Protein Sciences  as the manufacturer of Flublok 
Quadrivalent vaccin e has legal obligations to report safety information to various regulatory 
authorities. Accordingly, in the event that individual charts are reviewed and there is written 
notation in the medical record indicating that a health care provider attributed a SA E, S[LOCATION_003]R, or 
AESI to any product manufactured by [CONTACT_35346]/Protein Sciences used in the conduct of the research, KPVSC agrees to report all SAE s, S[LOCATION_003]R, and AESIs  possibly related to Flublok  
Quadrivalent vaccine. Pharmacovigilance reports to [COMPANY_011] Pa steur will be provided  at the address 
provided below  within 3 working days of KPVSCâ€™s awareness that a reportable SAE , S[LOCATION_003]R, or 
AESI  has occurred  to one of the two following addresses . 
â€¢ In PDF format to the following e -mail address, using a method of trans mission that 
includes password protection: CL -CPV -[EMAIL_5793]  
â€¢ By [CONTACT_29554], to the following address:  
Global Pharmacovigilance and Epi[INVESTIGATOR_623], [COMPANY_011] Pasteur Inc.,  
[ADDRESS_904186], Swiftwater, PA, [ZIP_CODE]- 0187, [LOCATION_003]  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 30 of 43 The reporting obligations as defined in the Study Agreement are the following:  
 
â€¢ Adverse events of special interest (AESI): anaphylactic reactions/hypersensitivity, 
pericarditis, Guillain -Barre Syndrome, neuritis, convulsion, encephalomyelitis/transverse 
myelitis, thrombocytopenia, syncope, vasculitis  
â€¢ Suspected Unexpected Serious Adverse Events (S[LOCATION_003]R): an adverse event, the nature or 
severity of which is not consistent with the applicable product information, such as a fatal  
outcome  
â€¢ New Safety Findings  
9.[ADDRESS_904187] be 
reported in the same procedure as explained in Section 9.1 ( within 3 working days of KPVSCâ€™s 
awareness ).  
9.[ADDRESS_904188] Has Completed the Study  
Any SAE  / AESI  that occurs after a subject has completed the study but that is likely to be related 
to Flublok Quadrivalent vaccine  must also be reported as soon as possible. In such a case, the 
reporting procedure to be followed is identical to that described in Section 9 .1. 
9.4 Assessment of Causality  
Not applicable for this EMR -based study.  
9.5 Reporting SAEs to Health Authorities and IECs / IRBs 
Please refer to Section 9.1.  KPVSC will perform the reporting of SAEs to Health Authorities and  
IECs  / IRBs in compliance with all applicable local and international pharmacovigilance laws and 
regulations.  
10 Data Collection and Management  
10.1 Data Collection  
Pertinent d ata will be extracted from the KPNC databases to create study datasets in the required 
file format for analysis (e.g., Excel spreadsheets, SAS datasets). Databases from which data will be extracted include various encounters (inpatient, outpatient, hospi[INVESTIGATOR_602], e mergency 
department, etc.), laboratory tests, documentation of immunizations (e.g., influenza vaccination history), and clinical outcomes and diagnoses, as well as demographic and membership data.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904189] will perform validation of  the study data throughout the data management 
process by [CONTACT_669501]:  
â€¢ Internal consistency checks (e.g. data undergo range checks, including consistency of 
dates of birth with vaccination dates, checks for comple teness and missing values, etc.)  
â€¢ External data checks (e.g. data from one database may be compared with data from other databases)  
â€¢ Error checks written for specific databases.  
10.[ADDRESS_904190] the null hypothesis that Flublok 
is not any more effective than the comparator  (i.e., a superiority test), using a [ADDRESS_904191], p<0.05.  
The primary analyses will use Cox regression to obtain an adjusted estimate of the relative hazard 
ratio ( rHR) for each outcome, adjusted for age, sex, race/ethnicity, facil ity, and time -since -
vaccination. The rHR at any point in the follow -up period is the instantaneous relative risk (RR) at 
that time (i.e., we are estimating rVE by (1 â€“rHR), and testing the null hypothesis that  rHR=0 ). In 
addition, we may adjust for an avail able comorbidity score and/or a measure of prior exposure to 
influenza vaccines (e.g., exposure to flu vaccine in the prior year, or number of flu shots in the 
past three years) . 
Risk sets will be conditioned (i.e., stratified) on  calendar day, using a cal endar timeline for the 
Cox regression. We expect many people to be vaccinated both years, and some might get 
â€œbreakthroughâ€ influenza both years . Getting Flublok in one year  should be entirely unrelated to 
getting Flublok in another year, so robust standard errors are not needed.  We will check our 
assumption that the vaccine received in one year is not rel ated to vaccine received the next year.   
For each type of outcome, foll ow-up would end at the first outcome event in a season but could 
restart the next year when the individual is vaccinated again.  
We do not know whether prior vaccination (i.e., booster or priming effect) affects VE of either Flublok Quadrivalent vaccine or SD-IIV, but we hypothesize that prior vaccination might be  an 
effect modifier but not  a potential confounder because what patients are vaccinated with in prior 
years should not be associated with what vaccine they receive in any of the 3 study seasons . We 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904192] to ascertain if, as expected, there is (1) no correlation between prior vaccination (before 
the study period) and vaccination during the  3 study seasons, and (2) no correlation between the  
type of vaccine received in one season and the type of va ccine received in any other  study 
season (s). If we find that there is a relationship in either of these scenarios, we can treat prior 
vaccination (â€œpriorâ€ meaning before the study commenced, or â€œpriorâ€ as in vaccination in the first 
study season relative t o the second study season) as a potential confounder. We would add 
variables that adjust for whether a patient was vaccinated  during the past year(s) , as well as which 
vaccine type they received. Further, if prior vaccination does modify VE , we may have ad equate 
power to assess whether there is a boosting effect given our large sample size.  
There is little possibility of confounding that may occur between patients tested versus those who 
are not tested. While not everyone with suspected influenza will be te sted, the randomization 
process in vaccine supply (Flublok Quadrivalent vaccine versus  SD-IIV) should result in an equal 
distribution of those who are and are not tested between the two vaccine groups throughout the season.  We will attempt to mitigate poss ible bias and confounding as much as possible upfront by 
[CONTACT_669515].  Because 
factors related to testing should be balanced, there is no reason to believe that the likelihood of 
being test ed will be related to whether a person received Flublok Quadrivalent vaccine or SD-IIV.  
We will also be monitoring the balance of potent ial confounders  that may be related to influenza 
and to PCR testing in order to confirm that we are achieving the balance intended by [CONTACT_669516] -
randomiz ed shipment of vaccines to clinics . Once vaccinations begin, we will monitor on a 
weekly basis the balan ce of Flublok vaccinees versus SD -IIV vaccinees with respect to facility, 
sex, and age group (18â€“49 years and 50â€“64 years). Additional demographic variables such as race and ethnicity may also be monitored . We will also monitor balance with respect to  como rbidit ies 
such as chronic obstructive pulmonary disease (COPD), asthma, and diabetes  (to be specified 
further  in the SAP) . If we find that any facility is using Flublok or SD -IIV more (or less) than 
needed to achieve balance, we will work with the influenz a program manager to adjust  what is 
being administered. If despi[INVESTIGATOR_180314], there is still imbalance, we can address these 
imbalances at the analysis stage, adjusting  for, or stratifying by , the relevant covariates .  
We plan to assess the outcomes that  occur  â‰¥[ADDRESS_904193] appropriate determination for h ow 
to handle such cases. 
  
For outcomes not based on PCR -confirmed influenza (e.g., hospi[INVESTIGATOR_669488]-
respi[INVESTIGATOR_29343]), we will develop an algorithm (to be described in the Statistical Analysis Plan) 
to measure the intensity of influenza circulation to guide when to start and stop following for such 
events (e.g., as determined by [CONTACT_8106], hospi[INVESTIGATOR_669489]).  
11.[ADDRESS_904194] rVE that is detectable with 80% power in a 3- year study for several aims. 
As described in Section 11.1, we plan to test the null hypothesis that Flublok is not any more effective than the comparator (i.e., a superiority test), using a [ADDRESS_904195], p<0.05. Our allocation 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page 33 of 43 ratio of 1:1 implies that each year, KPNC would give Flublok Quadrivalent vaccine to 400,000 
members aged 18 â€“64 years, and SD -IIV to another 400,000 similar KPNC members.    
Each row of the table s in the Appendices ( Section 1 5) shows power for a possible scenario for a 
given outcome and a specific age range. The expected incidence of the outcome in vaccinees who 
received SD-IIV (based on incidence observed in the 2016â€“2017 influenza season)  is in column 4; 
the relative risk ( estimated by [CONTACT_669517] ) associated with getting Flublok 
Quadrivalent vaccine versus a comparator is in column 5; the corresponding rVE in column 6; and 
the power in the last column. These power calculations estimate our power to test the  null 
hypothesis that Flublok Quadrivalent vaccine VE does not differ from SD -IIV(s).  
Because the comparison group will not be unvaccinatedâ€”they are getting SD-IIVâ€”we will be 
estimating and testing r VE: i.e., the percent reduction in the incidence of â€œbreakthrough casesâ€ 
(e.g., influenza epi[INVESTIGATOR_669490]) that results from the use of Flublok Quadrivalent vaccine 
rather than the SD -IIV vaccines.  
As an example, for the outcome of PCR -confirmed flu diagnosis, the first row of the first table 
indicates that p ower is very high (>0.99) to detect a rVE of 0.30 (which amounts to a 30% rVE) in 
a 3-year study of vaccinees aged 18â€“64 years, assuming that influenza incidence in the 
comparator arm will be the same as it was in the 2016 â€“[ADDRESS_904196] a rVE of 10% rather than 5% agai nst test -positive 
influenza in those aged 18â€“[ADDRESS_904197] subgroup analyses of rVE, including the subgroups  defined by:  
 
â€¢ influenza type A and B  
â€¢ selected diagnose s or conditions (e.g., in 50â€“64 year olds, rVE of those with specified 
comorbid conditions, such as cardiac, pulmonary, and metabolic comorbidities)  
â€¢ time periods and/or time -since -vaccination within a season  
â€¢ specific comparator SD -IIV(s) (if more than one comparator is used)  
12 Ethical and Legal Issues and Investigator  / Sponsor Responsibilities  
12.[ADDRESS_904198] of the Study  / Good Clinical Practice 
The conduct of this study will be consistent with the standards established by [CONTACT_35378]  / or national 
regulations and directives.  
12.2 Source Data and Source Documents 
The source data are stored in the KPNC EMR .  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904199] Records  
Prior to initiation of the study , the Investigator will sign a fully executed agreement, including 
confidentiality , with [COMPANY_011] Pasteur . [COMPANY_011] Pasteur personnel (or designates) will not have any 
access to subject records for the present st udy. All data reported to [COMPANY_011] Pasteur by [CONTACT_669518].  
12.[ADDRESS_904200] been created and maintained for use with the VSC  data management 
programs. These stored compi[INVESTIGATOR_669491] / P rogrammers 
for their use in constructing and testing programs.  
Changes made to programs after the start of a study are documented as notes i n the header/margin 
of the program  or in the appropriate revision control system . Changes are applied only to copi[INVESTIGATOR_669492], and the original source is retained indefinitely. It is incumbent upon the Data 
Analyst / P rogrammer in charge of a particular  task to document all programs  and work 
performed ; this includes code used as well as logs and listings produced.   
Programming for vaccine studies at the  KPVSC  adheres to standards across all projects to ensure 
the preservation of code, logs, and listings , as well as good programming in data processing and 
transparency in methodology.  
12.4.3  Archiving  
KPNC databases  created from KPNC EMRs  are available for research purposes to KPVSC Data 
Analysts / Programmers  for the duration that the project is open/approved by [CONTACT_669519] . 
Once the study is closed, the data are archived for future reference and regulatory compliance.  
  
12.[ADDRESS_904201] and Insurance Coverage  
Not applicable.  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904202] , 
provided that KPVSCâ€™s investigator will lead all such publications and presentations. [COMPANY_011] 
Pasteur /Protein  Sciences  will not manipulate or reanalyze the results of the Research Project in 
any way. No less than thirty (30) days prior to submission to a publisher or any external forum, 
each Party shall provide the other party with a copy of any proposed publicat ion or presentation 
for review and comment, which review shall be limited to determining whether the publication or 
presentation includes the disclosure of Confidential Information or patentable subject matter. 
Publications or presentations shall not include Protected Health Information" or "PHI," or the 
Confidential Information of the other Party (other than the final aggregated re search results of the 
Research Project ) without the written permission of such Party. If the reviewing Party believes 
that pate ntable subject matter is disclosed in the manuscript or presentation and so notifies the 
publishing Party in writing within the thirty (30) day review period, said publication will be 
withheld for a reasonable period of time (but not to exceed sixty (60) days) until all applicable 
patent filings are completed. With respect to public presentations, each Party shall use reasonable 
efforts to provide review and comments more promptly than the full period of review specified in 
this Section, if requested by [CONTACT_669520].    
Qualification for authorship and contributorship shall be determined in accordance with the â€œUniform Requirements for Manuscripts Submitted to Biomedical Journals,â€ published by [CONTACT_19483] ( ICMJE). Publications shall carry appropriate 
acknowledgment of funding support from [COMPANY_011] Pasteur and a disclaimer that the contents are the responsibility of the authors and do not necessarily represent the official views of Institution.  
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904203]  
 
 
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904204] this trial according to the procedures outlined in 
the protocol, to comply with its requirements, related to ethical and safety considerations, and to comply with applicable regulations and Good Clinical Practice.  
 
         
Nicola Klein, MD, PhD    Date  
Principal Investigator  
 
[INVESTIGATOR_669493]/Proprietary Information  
Page [ADDRESS_904205]  5 types of outcome  events 
By [CONTACT_551] (or chronic  disease status)  and outcome  
2-sided  alpha=0.05 (likelihood ratio  chi-sq test for superiority)  
800,000  vaccinees expected  per yr: 400K fluBlok  v. 400K comparators 
 
 
 
age=18 -64 outcome=flu,  test+  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904206] the 
outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
1 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.70 0.30 >.99 
2 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.75 0.25 >.99 
3 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.80 0.20 >.99 
4 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.85 0.15 >.99 
5 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.90 0.10 0.96 
6 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.95 0.05 0.45 
 
age=18 -64 outcome=hosp,  flutest+  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904207] the 
outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
7 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.70 0.30 >.99 
8 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.75 0.25 >.99 
9 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.80 0.20 >.99 
10 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.85 0.15 0.95 
11 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.90 0.10 0.66 
12 1,200 ,000 1,200 ,000 0.[ZIP_CODE]  0.95 0.05 0.22 
  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904208]  5 types of outcome  events 
By [CONTACT_551] (or chronic  disease status)  and outcome  
2-sided  alpha=0.05 (likelihood ratio  chi-sq test for superiority)  
800,000  vaccinees expected  per yr: 400K fluBlok  v. 400K comparators 
 
age=18 -49 outcome=flu,  test+  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904209] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
13 680,301  680,301  0.[ZIP_CODE]  0.70 0.30 >.99 
14 680,301  680,301  0.[ZIP_CODE]  0.75 0.25 >.99 
15 680,301  680,301  0.[ZIP_CODE]  0.80 0.20 >.99 
16 680,301  680,301  0.[ZIP_CODE]  0.85 0.15 >.99 
17 680,301  680,301  0.[ZIP_CODE]  0.90 0.10 0.82 
18 680,301  680,301  0.[ZIP_CODE]  0.95 0.05 0.29 
 
age=18 -49 outcome=hosp,  flutest+  
 
  
 
row  
 
N expectd  
[ADDRESS_904210] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
19 680,301  680,301  0.[ZIP_CODE]  0.70 0.30 >.99 
20 680,301  680,301  0.[ZIP_CODE]  0.75 0.25 0.98 
21 680,301  680,301  0.[ZIP_CODE]  0.80 0.20 0.88 
22 680,301  680,301  0.[ZIP_CODE]  0.85 0.15 0.64 
23 680,301  680,301  0.[ZIP_CODE]  0.90 0.10 0.33 
24 680,301  680,301  0.[ZIP_CODE]  0.95 0.05 0.12 
  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904211]  5 types of outcome  events 
By [CONTACT_551] (or chronic  disease status)  and outcome  
2-sided  alpha=0.05 (likelihood ratio  chi-sq test for superiority)  
800,000  vaccinees expected  per yr: 400K fluBlok  v. 400K comparators 
 
age=50 -64 outcome=flu,  test+  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904212] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
25 519,699  519,699  0.[ZIP_CODE]  0.70 0.30 >.99 
26 519,699  519,699  0.[ZIP_CODE]  0.75 0.25 >.99 
27 519,699  519,699  0.[ZIP_CODE]  0.80 0.20 >.99 
28 519,699  519,699  0.[ZIP_CODE]  0.85 0.15 0.95 
29 519,699  519,699  0.[ZIP_CODE]  0.90 0.10 0.66 
30 519,699  519,699  0.[ZIP_CODE]  0.95 0.05 0.22 
 
age=50 -64 outcome=hosp,  flutest+  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904213] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
31 519,699  519,699  0.[ZIP_CODE]  0.70 0.30 >.99 
32 519,699  519,699  0.[ZIP_CODE]  0.75 0.25 >.99 
33 519,699  519,699  0.[ZIP_CODE]  0.80 0.20 0.96 
34 519,699  519,699  0.[ZIP_CODE]  0.85 0.15 0.79 
35 519,699  519,699  0.[ZIP_CODE]  0.90 0.10 0.44 
36 519,699  519,699  0.[ZIP_CODE]  0.95 0.05 0.15 
 
age=50 -64  outcome=PneumoniaHosp,Dec -March  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904214] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
37 519,699  519,699  0.[ZIP_CODE]  0.70 0.30 >.99 
38 519,699  519,699  0.[ZIP_CODE]  0.75 0.25 >.99 
39 519,699  519,699  0.[ZIP_CODE]  0.80 0.20 >.99 
40 519,699  519,699  0.[ZIP_CODE]  0.85 0.15 0.98 
41 519,699  519,699  0.[ZIP_CODE]  0.90 0.10 0.74 
42 519,699  519,699  0.[ZIP_CODE]  0.95 0.05 0.25 
 
  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904215]  5 types  of outcome  events   
By [CONTACT_551]  (or chronic  disease status)  and outcome  
2-sided  alpha=0.05 (likelihood ratio chi-sq test for superiority)   
800,000  vaccinees expected  per yr: 400K fluBlok  v. 400K comparators  
 
age=50 -64 outcome=CVD  hosp, Dec-March  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904216] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
43 519,699  519,699  0.[ZIP_CODE]  0.70 0.30 >.99 
44 519,699  519,699  0.[ZIP_CODE]  0.75 0.25 >.99 
45 519,699  519,699  0.[ZIP_CODE]  0.80 0.20 >.99 
46 519,699  519,699  0.[ZIP_CODE]  0.85 0.15 >.99 
47 519,699  519,699  0.[ZIP_CODE]  0.90 0.10 0.99 
48 519,699  519,699  0.[ZIP_CODE]  0.95 0.05 0.53 
 
age=50 -64 outcome=all  hosp,  Dec-March  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904217] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
49 519,699  519,699  0.[ZIP_CODE]  0.70 0.30 >.99 
50 519,699  519,699  0.[ZIP_CODE]  0.75 0.25 >.99 
51 519,699  519,699  0.[ZIP_CODE]  0.80 0.20 >.99 
52 519,699  519,699  0.[ZIP_CODE]  0.85 0.15 >.99 
53 519,699  519,699  0.[ZIP_CODE]  0.90 0.10 >.99 
54 519,699  519,699  0.[ZIP_CODE]  0.95 0.05 >.99 
 
  
 
 
  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904218]  5 types  of outcome  events   
By [CONTACT_551]  (or chronic  disease status)  and outcome  
2-sided  alpha=0.05 (likelihood ratio chi-sq test for superiority)   
800,000  vaccinees expected  per yr: 400K fluBlok  v. 400K comparators  
age=ChronicDis,50 -64 outcome=flu,  test+  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904219] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
55 103,940  103,940  0.[ZIP_CODE]  0.70 0.30 0.98 
56 103,940  103,940  0.[ZIP_CODE]  0.75 0.25 0.9 
57 103,940  103,940  0.[ZIP_CODE]  0.80 0.20 0.73 
58 103,940  103,940  0.[ZIP_CODE]  0.85 0.15 0.48 
59 103,940  103,940  0.[ZIP_CODE]  0.90 0.10 0.24 
60 103,940  103,940  0.[ZIP_CODE]  0.95 0.05 0.09 
 
age=ChronicDis,50 -64 outcome=hosp,  flutest+  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904220] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
61 103,940  103,940  0.[ZIP_CODE]  0.70 0.30 0.91 
62 103,940  103,940  0.[ZIP_CODE]  0.75 0.25 0.78 
63 103,940  103,940  0.[ZIP_CODE]  0.80 0.20 0.58 
64 103,940  103,940  0.[ZIP_CODE]  0.85 0.15 0.36 
65 103,940  103,940  0.[ZIP_CODE]  0.90 0.10 0.18 
66 103,940  103,940  0.[ZIP_CODE]  0.95 0.05 0.08 
 
age=ChronicDis,50 -64  outcome=PneumoniaHosp,Dec -March  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904221] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
67 103,940  103,940  0.[ZIP_CODE]  0.70 0.30 >.99 
68 103,940  103,940  0.[ZIP_CODE]  0.75 0.25 >.99 
69 103,940  103,940  0.[ZIP_CODE]  0.80 0.20 0.99 
70 103,940  103,940  0.[ZIP_CODE]  0.85 0.15 0.87 
71 103,940  103,940  0.[ZIP_CODE]  0.90 0.10 0.53 
72 103,940  103,940  0.[ZIP_CODE]  0.95 0.05 0.17 
 
  
Kaiser Permanente Vaccine Study Center    
 
Confidential/Proprietary Information  
Page [ADDRESS_904222]  5 types  of outcome  events   
By [CONTACT_551]  (or chronic  disease status)  and outcome  
2-sided  alpha=0.05 (likelihood ratio chi-sq test for superiority)   
800,000  vaccinees expected  per yr: 400K fluBlok  v. 400K comparators  
 
age=ChronicDis,50 -64 outcome=CVD  hosp,  Dec-March  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904223] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
73 103,940  103,940  0.[ZIP_CODE]  0.70 0.30 >.99 
74 103,940  103,940  0.[ZIP_CODE]  0.75 0.25 >.99 
75 103,940  103,940  0.[ZIP_CODE]  0.80 0.20 >.99 
76 103,940  103,940  0.[ZIP_CODE]  0.85 0.15 >.99 
77 103,940  103,940  0.[ZIP_CODE]  0.90 0.10 0.9 
78 103,940  103,940  0.[ZIP_CODE]  0.95 0.05 0.36 
 
age=ChronicDis,50 -64 outcome=all  hosp, Dec-March  
 
 
 
 
row  
 
N expectd  
[ADDRESS_904224] 
the outcome   
RR = 
1 minus  
relative  
VE Relative VE: 
% of 
breakthru  
cases  
prevented  Power  
(prob.  of 
rejecting  Ho 
if rel_VE  
is true)  
79 103,940  103,940  0.[ZIP_CODE]  0.70 0.30 >.99 
80 103,940  103,940  0.[ZIP_CODE]  0.75 0.25 >.99 
81 103,940  103,940  0.[ZIP_CODE]  0.80 0.20 >.99 
82 103,940  103,940  0.[ZIP_CODE]  0.85 0.15 >.99 
83 103,940  103,940  0.[ZIP_CODE]  0.90 0.10 >.99 
84 103,940  103,940  0.[ZIP_CODE]  0.95 0.05 0.97 
 
 